Virpax Pharmaceuticals Ownership
| VRPX Stock | USD 0.46 0.02 4.17% |
Shares in Circulation | First Issued 2019-12-31 | Previous Quarter 2 M | Current Value 4.7 M | Avarage Shares Outstanding 4.7 M | Quarterly Volatility 3.5 M |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Virpax |
Virpax Stock Ownership Analysis
The company has Price to Book (P/B) ratio of 0.48. Historically many companies with similar price-to-book (P/B) ratio do better than the market in the long run. Virpax Pharmaceuticals recorded a loss per share of 13.25. The entity had not issued any dividends in recent years. The firm had 1:10 split on the 1st of March 2024. Virpax Pharmaceuticals, Inc., a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system disorders. Virpax Pharmaceuticals, Inc. was founded in 2016 and is headquartered in Berwyn, Pennsylvania. Virpax Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 7 people. For more information please call Anthony MBA at 610-727-4597 or visit https://www.virpaxpharma.com.Besides selling stocks to institutional investors, Virpax Pharmaceuticals also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Virpax Pharmaceuticals' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Virpax Pharmaceuticals' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Virpax Pharmaceuticals Quarterly Liabilities And Stockholders Equity |
|
Roughly 3.0% of Virpax Pharmaceuticals are currently held by insiders. Unlike Virpax Pharmaceuticals' institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Virpax Pharmaceuticals' private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Virpax Pharmaceuticals' insider trades
Virpax Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Virpax Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Virpax Pharmaceuticals backward and forwards among themselves. Virpax Pharmaceuticals' institutional investor refers to the entity that pools money to purchase Virpax Pharmaceuticals' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Garden State Investment Advisory Services Llc | 2024-09-30 | 57.3 K | Citadel Advisors Llc | 2024-09-30 | 31.4 K | Geode Capital Management, Llc | 2024-09-30 | 28 K | Warberg Asset Management Llc | 2024-06-30 | 20 K | Tower Research Capital Llc | 2024-06-30 | 3.1 K | Ubs Group Ag | 2024-06-30 | 1.1 K | Signature Resources Capital Management, Llc | 2024-09-30 | 50.0 | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 30.0 | Hantz Financial Services, Inc. | 2024-06-30 | 10.0 | Bank Of America Corp | 2024-06-30 | 7.0 | Wells Fargo & Co | 2024-06-30 | 0.0 |
Virpax Pharmaceuticals Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Virpax Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Virpax Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Virpax Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Virpax Pharmaceuticals Outstanding Bonds
Virpax Pharmaceuticals issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Virpax Pharmaceuticals uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Virpax bonds can be classified according to their maturity, which is the date when Virpax Pharmaceuticals has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View | |
| VISA INC 365 Corp BondUS92826CAJ18 | View | |
| VISA INC 275 Corp BondUS92826CAH51 | View | |
| VISA INC 43 Corp BondUS92826CAF95 | View |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Virpax Stock Analysis
When running Virpax Pharmaceuticals' price analysis, check to measure Virpax Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Virpax Pharmaceuticals is operating at the current time. Most of Virpax Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Virpax Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Virpax Pharmaceuticals' price. Additionally, you may evaluate how the addition of Virpax Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.